<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04332627</url>
  </required_header>
  <id_info>
    <org_study_id>B-1910/571-004</org_study_id>
    <nct_id>NCT04332627</nct_id>
  </id_info>
  <brief_title>Comparison of QoR-15 in Laparoscopic Cholecystectomy: Sugammadex vs. Neostigmine</brief_title>
  <official_title>Comparison of Quality of Recovery Score (QoR-15) According to Neuromuscular Blocking Reversal Agent in Laparoscopic Cholecystectomy: Sugammadex vs. Neostigmine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The quality of recovery in patients who were reversed neuromuscular blockade by using&#xD;
      Sumamadex and Neostigmine in laparoscopic cholecystectomy was compared through the&#xD;
      QoR(Quality of Recovery)-15 questionnaire.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Quality of Recovery questionnaire includes five details (Emotional status, Physical comfort,&#xD;
      Physiological support, Physical independece, Pain), and is a proven method of reliability,&#xD;
      consistency and validity for evaluating recovery from surgery and anesthesia.&#xD;
&#xD;
      After laparoscopic cholecystectomy, patients experience various discomforts such as pain,&#xD;
      nausea, vomiting, and placebo due to general anesthesia.&#xD;
&#xD;
      Neostigmine has side effects such as crampy abdominal pain, nausea and vomiting. In addition,&#xD;
      residual neuromuscular blockade was higher in neostigmine compared with sugammadex.&#xD;
&#xD;
      Although sugammadex expected to improve patient's recovery, it is still controversial that&#xD;
      sugammadex contributes to clinically meaningfull difference compared with neostigmine.&#xD;
&#xD;
      Therefore, the aim of our study is comparison of quality of recovery through QoR-15&#xD;
      questionnaire in patients who were reversed neuromuscular blockade by using sugammadex and&#xD;
      neostigmine in laparoscopic cholecystectomy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Actual">May 21, 2020</completion_date>
  <primary_completion_date type="Actual">May 21, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Recovery(QoR)-15 questionnaire score</measure>
    <time_frame>preoperative 1 days to postoperative 2 days</time_frame>
    <description>the difference of Quality of Recovery(QoR)-15 score between preoperative and postoperative 1 and 2 days (minimum value : 0, maximum value : 150, the higher the score, the better the result)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>recovery time</measure>
    <time_frame>perioperative - until 48hours</time_frame>
    <description>from injection of sugammadex or neostigmien to extubation and confirm of adequate spontaneous breathing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PACU(post-anesthesia care unit) stay time</measure>
    <time_frame>perioperative - until 48hours</time_frame>
    <description>from entry of PACU to go general ward</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative pain score</measure>
    <time_frame>at postoperative 30minutes, 6hours, 24hours</time_frame>
    <description>postoperative pain score measured by 11-point NRS(numerical rating scale) score (minimum : 0, maximum : 11, the lower the score, the lesser pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the incidence of administration of postoperative rescue drug</measure>
    <time_frame>perioperative - until 72hours</time_frame>
    <description>administration of analgesic drug and anti-emetic drug for postoperative management</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital stay</measure>
    <time_frame>preoperative - until discharge (usually 48 hours to 72hours)</time_frame>
    <description>days of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary retention</measure>
    <time_frame>postoperative - until discharge (usually 48 hours to 72hours)</time_frame>
    <description>residual urine &gt; 300ml diagnosed by bladder ultrasonography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Neuromuscular Blockade Reversal Agent</condition>
  <condition>Sugammadex</condition>
  <condition>Neostigmine</condition>
  <condition>Quality of Recovery</condition>
  <condition>Laparoscopic Cholecystectomy</condition>
  <arm_group>
    <arm_group_label>sugammadex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sugammadex 2mg/kg or 4mg/kg according to Train-of-four count (TOF 0 : 4mg/kg, TOF 1-4 : 2mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>neostigmine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>with glycopyrrolate 0.4mg, neostigmine 0.02mg/kg or 0.04mg/kg or 0.05mg/kg according to Train-of-four count (TOF 0 : wait until TOF 2, TOF2-3: 0.05mg/kg, TOF4: 0.04mg/kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>sugammadex 2mg/kg or 4mg/kg according to Train-of-four count (TOF 0 : 4mg/kg, TOF 1-4 : 2mg/kg)</description>
    <arm_group_label>sugammadex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>with glycopyrrolate 0.4mg, neostigmine 0.02mg/kg or 0.04mg/kg or 0.05mg/kg according to Train-of-four count (TOF 0 : wait until TOF 2, TOF2-3: 0.05mg/kg, TOF4: 0.04mg/kg)</description>
    <arm_group_label>neostigmine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients who underwent laparoscopic cholecystectomy aged 20-70&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  neuromuscular disease&#xD;
&#xD;
          -  allergy to rocuronium, sugammadex, neostigmine&#xD;
&#xD;
          -  cognitive impairment ( disable to answer the questionnaire )&#xD;
&#xD;
          -  refuse to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiwon Han, Ms</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Stark PA, Myles PS, Burke JA. Development and psychometric evaluation of a postoperative quality of recovery score: the QoR-15. Anesthesiology. 2013 Jun;118(6):1332-40. doi: 10.1097/ALN.0b013e318289b84b.</citation>
    <PMID>23411725</PMID>
  </reference>
  <reference>
    <citation>Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev. 2017 Aug 14;8:CD012763. doi: 10.1002/14651858.CD012763. Review.</citation>
    <PMID>28806470</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>JiWon Han</investigator_full_name>
    <investigator_title>clinical instructor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

